Kathleen L Poston, MD
Neurology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 5
- 2 carriers
- Office
- 1
Offices
1 location · Stanford Health Care · 3,152 clinicians in this group
Looking this up.
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
5 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Poston’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
5 of 5 plans
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A86599 · Current
Licensed to practise in California · since 2004 · expires 2027-08-31 · Vanderbilt University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$18,760
Medicare paid this office $18,760 for 58 people. Most of that is long return visits and Botox.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Long return visit (40+ min) | 44 | $7,996 | $111 |
| Injection of chemical for paralysis of salivary glands on both sides of mouth | 11 | $2,399 | $89 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 35 | $599 | $15 |
Who their Medicare patients are
58 Original Medicare patients in 2024. Average age 76 · Women 48% · Health risk score 1.31. At or below the middle of the specialty; the typical neurology clinician is at 1.61.
Conditions among them: High blood pressure 60% · Depression 33% · Dementia 24% · Coronary heart disease 22%.
The office billed $80,171, Medicare allowed $26,126 and paid $18,760; for 229 services of 12 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 58 | 229 | 76 | 1.31 | $80,171 | $18,760 |
| 2023 | 64 | 199 | 75 | 1.20 | $69,266 | $19,297 |
| 2022 | 74 | 256 | 75 | 1.24 | $84,994 | $23,576 |
| 2021 | 71 | 233 | 75 | 1.29 | $80,054 | $21,953 |
| 2020 | 75 | 226 | 74 | 1.31 | $85,845 | $18,216 |
| 2019 | 89 | 228 | 75 | 1.40 | $50,114 | $19,412 |
| 2018 | 91 | 290 | 75 | 1.43 | $69,924 | $24,898 |
| 2017 | 108 | 259 | 75 | 1.39 | $72,625 | $20,999 |
| 2016 | 117 | 283 | 75 | 1.50 | $94,229 | $25,779 |
| 2015 | 140 | 307 | 74 | 1.47 | $92,285 | $26,963 |
| 2014 | 117 | 237 | 73 | 1.40 | $72,169 | $20,538 |
| 2013 | 114 | 260 | 73 | 1.34 | $77,268 | $22,848 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 2 services
| Long return visit (40+ min) | 48 | $11,771 | $120 |
| Muscle electrical test | 11 | $387 | $15 |
2022: 3 services
| Long return visit (40+ min) | 58 | $13,768 | $116 |
| Return visit (30+ min) | 11 | $998 | $77 |
| Muscle electrical test | 14 | $613 | $16 |
2021: 2 services
| Long return visit (40+ min) | 57 | $14,637 | $116 |
| Return visit (30+ min) | 20 | $1,869 | $85 |
2020: 3 services
| Long return visit (40+ min) | 59 | $12,322 | $91 |
| Long return visit (40+ min) | 12 | $839 | $70 |
| Return visit (30+ min) | 13 | $815 | $63 |
2019: 2 services
| Long return visit (40+ min) | 73 | $13,187 | $90 |
| Return visit (30+ min) | 11 | $634 | $53 |
2018: 2 services
| Long return visit (40+ min) | 79 | $13,973 | $88 |
| Long return visit (40+ min) | 37 | $4,290 | $100 |
2017: 1 service
| Long return visit (40+ min) | 93 | $15,006 | $86 |
2016: 1 service
| Long return visit (40+ min) | 103 | $19,690 | $97 |
2015: 2 services
| Long return visit (40+ min) | 117 | $19,452 | $91 |
| New patient visit (60+ min) | 17 | $2,136 | $126 |
2014: 2 services
| Long return visit (40+ min) | 88 | $13,541 | $85 |
| New patient visit (60+ min) | 24 | $3,332 | $139 |
2013: 3 services
| Long return visit (40+ min) | 74 | $11,211 | $85 |
| New patient visit (60+ min) | 16 | $2,318 | $145 |
| Return visit (30+ min) | 16 | $1,157 | $61 |
Drugs they prescribed that Part D paid
$240,578
Pharmacies billed $240,578 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
516 generic and 56 brand-name prescriptions · $240,578 in drug cost · 37 antipsychotic prescriptions to people over 65.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Nuplazid | Parkinson's psychosis | 18 | $117,553 | $6,531 |
| Rytary | Parkinson's | 16 | $39,911 | $2,494 |
| Droxidopa | None | 13 | $25,165 | $1,936 |
| Carbidopa-Levodopa | None | 98 | $4,364 | $45 |
| Carbidopa-Levodopa Er | None | 60 | $3,539 | $59 |
See all 14 drugs
| Nuplazid | Parkinson's psychosis | 18 | $117,553 | $6,531 |
| Rytary | Parkinson's | 16 | $39,911 | $2,494 |
| Droxidopa | None | 13 | $25,165 | $1,936 |
| Carbidopa-Levodopa | None | 98 | $4,364 | $45 |
| Carbidopa-Levodopa Er | None | 60 | $3,539 | $59 |
| Amantadine | None | 16 | $1,207 | $75 |
| Mirtazapine | None | 44 | $956 | $22 |
| Quetiapine | None | 19 | $927 | $49 |
| Clonazepam | None | 61 | $753 | $12 |
| Memantine | None | 15 | $597 | $40 |
| Clomipramine | None | 12 | $428 | $36 |
| Donepezil | None | 21 | $417 | $20 |
| Levetiracetam | None | 12 | $117 | $10 |
| Lamotrigine | None | 20 | $68 | $3 |
Year by year
| 2024 | 572 | 48 | None | 10% | $240,578 |
| 2023 | 615 | 56 | None | 13% | $300,596 |
| 2022 | 634 | 56 | None | 14% | $328,841 |
| 2021 | 641 | 46 | None | 12% | $231,235 |
| 2020 | 732 | 58 | 0% (0) | 10% | $200,937 |
| 2019 | 766 | 66 | 0% (0) | 15% | $225,133 |
| 2018 | 847 | 84 | 0% (0) | 17% | $277,263 |
| 2017 | 962 | 74 | 0% (0) | 18% | $306,741 |
| 2016 | 1,140 | 84 | 0% (0) | 17% | $278,314 |
| 2015 | 968 | 84 | 0% (0) | 20% | $151,327 |
| 2014 | 742 | 75 | 0% (0) | 20% | $108,980 |
| 2013 | 606 | 64 | 0% (0) | 20% | $107,774 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 14 drugs
| Nuplazid | Parkinson's psychosis | 31 | $159,413 | $5,142 |
| Rytary | Parkinson's | 19 | $45,179 | $2,378 |
| Myrbetriq | None | 15 | $15,479 | $1,032 |
| Carbidopa-Levodopa | None | 112 | $8,719 | $78 |
| Clomipramine | None | 12 | $5,834 | $486 |
| Carbidopa-Levodopa Er | None | 70 | $3,791 | $54 |
| Amantadine | None | 28 | $2,056 | $73 |
| Clonazepam | None | 73 | $1,686 | $23 |
| Midodrine | None | 15 | $1,659 | $111 |
| Quetiapine | None | 35 | $1,477 | $42 |
| Mirtazapine | None | 44 | $1,210 | $28 |
| Fludrocortisone Acetate | None | 14 | $848 | $61 |
| Donepezil | None | 19 | $511 | $27 |
| Levetiracetam | None | 12 | $317 | $26 |
2022: 17 drugs
| Nuplazid | Parkinson's psychosis | 34 | $161,802 | $4,759 |
| Rytary | Parkinson's | 23 | $54,041 | $2,350 |
| Pramipexole Er | None | 16 | $15,927 | $995 |
| Carbidopa-Levodopa | None | 101 | $9,483 | $94 |
| Rasagiline Mesylate | None | 16 | $8,918 | $557 |
| Carbidopa-Levodopa Er | None | 62 | $4,871 | $79 |
| Amantadine | None | 34 | $3,265 | $96 |
| Midodrine | None | 14 | $1,478 | $106 |
| Quetiapine | None | 32 | $1,196 | $37 |
| Fludrocortisone Acetate | None | 14 | $1,082 | $77 |
| Mirtazapine | None | 35 | $1,006 | $29 |
| Clonazepam | None | 60 | $958 | $16 |
| Clomipramine | None | 12 | $634 | $53 |
| Donepezil | None | 22 | $336 | $15 |
| Gabapentin | None | 11 | $287 | $26 |
| Lamotrigine | None | 33 | $202 | $6 |
| Levetiracetam | None | 12 | $172 | $14 |
2021: 17 drugs
| Nuplazid | Parkinson's psychosis | 25 | $102,246 | $4,090 |
| Neupro | None | 18 | $33,190 | $1,844 |
| Rytary | Parkinson's | 11 | $24,454 | $2,223 |
| Carbidopa-Levodopa | None | 112 | $10,254 | $92 |
| Rasagiline Mesylate | None | 23 | $7,187 | $312 |
| Selegiline | None | 26 | $4,523 | $174 |
| Carbidopa-Levodopa Er | None | 58 | $4,492 | $77 |
| Amantadine | None | 36 | $3,472 | $96 |
| Entacapone | None | 18 | $2,556 | $142 |
| Clonazepam | None | 66 | $1,045 | $16 |
| Fludrocortisone Acetate | None | 12 | $964 | $80 |
| Mirtazapine | None | 30 | $923 | $31 |
| Quetiapine | None | 28 | $637 | $23 |
| Donepezil | None | 31 | $477 | $15 |
| Clomipramine | None | 12 | $460 | $38 |
| Levetiracetam | None | 12 | $302 | $25 |
| Lamotrigine | None | 37 | $238 | $6 |
2020: 19 drugs
| Neupro | None | 23 | $34,760 | $1,511 |
| Rytary | Parkinson's | 15 | $33,299 | $2,220 |
| Rasagiline Mesylate | None | 24 | $17,249 | $719 |
| Pramipexole Er | None | 19 | $16,382 | $862 |
| Carbidopa-Levodopa | None | 147 | $12,010 | $82 |
| Selegiline | None | 35 | $5,516 | $158 |
| Carbidopa-Levodopa Er | None | 68 | $4,970 | $73 |
| Amantadine | None | 35 | $4,210 | $120 |
| Clomipramine | None | 12 | $3,207 | $267 |
| Entacapone | None | 23 | $2,904 | $126 |
| Fludrocortisone Acetate | None | 23 | $1,037 | $45 |
| Clonazepam | None | 64 | $805 | $13 |
| Mirtazapine | None | 30 | $805 | $27 |
| Donepezil | None | 38 | $609 | $16 |
| Quetiapine | None | 23 | $522 | $23 |
| Gabapentin | None | 21 | $511 | $24 |
| Levetiracetam | None | 12 | $285 | $24 |
| Lamotrigine | None | 34 | $227 | $7 |
| Bupropion Xl | None | 13 | $157 | $12 |
2019: 20 drugs
| Neupro | None | 24 | $31,283 | $1,303 |
| Rytary | Parkinson's | 19 | $30,416 | $1,601 |
| Rasagiline Mesylate | None | 28 | $24,337 | $869 |
| Pramipexole Er | None | 15 | $16,993 | $1,133 |
| Carbidopa-Levodopa-Entacapone | None | 15 | $13,436 | $896 |
| Carbidopa-Levodopa | None | 145 | $11,339 | $78 |
| Amantadine | None | 59 | $7,140 | $121 |
| Selegiline | None | 37 | $5,488 | $148 |
| Entacapone | None | 30 | $4,980 | $166 |
| Clomipramine | None | 13 | $4,973 | $383 |
| Carbidopa-Levodopa Er | None | 57 | $4,343 | $76 |
| Midodrine | None | 13 | $1,210 | $93 |
| Clonazepam | None | 62 | $1,140 | $18 |
| Fludrocortisone Acetate | None | 14 | $651 | $46 |
| Mirtazapine | None | 24 | $547 | $23 |
| Gabapentin | None | 30 | $535 | $18 |
| Donepezil | None | 26 | $513 | $20 |
| Quetiapine | None | 24 | $503 | $21 |
| Levetiracetam | None | 12 | $207 | $17 |
| Lamotrigine | None | 24 | $132 | $6 |
2018: 21 drugs
| Nuplazid | Parkinson's psychosis | 18 | $68,265 | $3,792 |
| Rasagiline Mesylate | None | 32 | $34,931 | $1,092 |
| Neupro | None | 19 | $23,014 | $1,211 |
| Rytary | Parkinson's | 19 | $20,880 | $1,099 |
| Carbidopa-Levodopa | None | 182 | $11,513 | $63 |
| Entacapone | None | 32 | $10,619 | $332 |
| Pramipexole Er | None | 16 | $9,787 | $612 |
| Amantadine | None | 65 | $7,488 | $115 |
| Carbidopa-Levodopa Er | None | 65 | $4,744 | $73 |
| Selegiline | None | 42 | $4,530 | $108 |
| Clomipramine | None | 13 | $4,137 | $318 |
| Rivastigmine | None | 11 | $3,905 | $355 |
| Ropinirole Er | None | 14 | $3,202 | $229 |
| Donepezil | None | 50 | $888 | $18 |
| Clonazepam | None | 48 | $818 | $17 |
| Gabapentin | None | 26 | $471 | $18 |
| Quetiapine | None | 18 | $436 | $24 |
| Mirtazapine | None | 16 | $387 | $24 |
| Levetiracetam | None | 13 | $372 | $29 |
| Pramipexole Dihydrochloride | None | 12 | $175 | $15 |
| Lamotrigine | None | 22 | $120 | $5 |
2017: 22 drugs
| Azilect | None | 33 | $36,515 | $1,107 |
| Rasagiline Mesylate | None | 23 | $27,102 | $1,178 |
| Neupro | None | 30 | $25,810 | $860 |
| Pramipexole Er | None | 23 | $13,414 | $583 |
| Entacapone | None | 29 | $13,295 | $458 |
| Carbidopa-Levodopa | None | 206 | $11,707 | $57 |
| Rytary | Parkinson's | 11 | $10,896 | $991 |
| Amantadine | None | 79 | $8,635 | $109 |
| Carbidopa-Levodopa-Entacapone | None | 13 | $8,316 | $640 |
| Selegiline | None | 49 | $6,096 | $124 |
| Clomipramine | None | 12 | $4,534 | $378 |
| Carbidopa-Levodopa Er | None | 82 | $4,388 | $54 |
| Ropinirole Er | None | 12 | $3,370 | $281 |
| Donepezil | None | 67 | $1,219 | $18 |
| Memantine | None | 29 | $1,197 | $41 |
| Clonazepam | None | 47 | $744 | $16 |
| Mirtazapine | None | 23 | $516 | $22 |
| Levetiracetam | None | 12 | $314 | $26 |
| Gabapentin | None | 17 | $277 | $16 |
| Pramipexole Dihydrochloride | None | 16 | $223 | $14 |
| Quetiapine | None | 11 | $111 | $10 |
| Lamotrigine | None | 12 | $78 | $6 |
2016: 27 drugs
| Azilect | None | 62 | $58,655 | $946 |
| Neupro | None | 29 | $20,681 | $713 |
| Pramipexole Er | None | 36 | $16,535 | $459 |
| Entacapone | None | 32 | $11,347 | $355 |
| Carbidopa-Levodopa | None | 229 | $9,648 | $42 |
| Modafinil | None | 14 | $9,286 | $663 |
| Rytary | Parkinson's | 14 | $7,618 | $544 |
| Amantadine | None | 74 | $7,284 | $98 |
| Selegiline | None | 54 | $5,728 | $106 |
| Memantine | None | 39 | $4,853 | $124 |
| Clomipramine | None | 12 | $4,484 | $374 |
| Carbidopa-Levodopa Er | None | 99 | $3,186 | $32 |
| Ropinirole Er | None | 14 | $2,326 | $166 |
| Sinemet 25-100 | None | 13 | $2,203 | $169 |
| Pramipexole Dihydrochloride | None | 20 | $1,183 | $59 |
| Clonazepam | None | 60 | $1,002 | $17 |
| Donepezil | None | 72 | $994 | $14 |
| Midodrine | None | 14 | $614 | $44 |
| Bupropion Xl | None | 21 | $600 | $29 |
| Gabapentin | None | 21 | $325 | $15 |
| Mirtazapine | None | 18 | $314 | $17 |
| Ropinirole | None | 19 | $303 | $16 |
| Quetiapine | None | 22 | $280 | $13 |
| Propranolol | None | 11 | $235 | $21 |
| Levetiracetam | None | 12 | $117 | $10 |
| Lamotrigine | None | 12 | $98 | $8 |
| Lorazepam | None | 13 | $31 | $2 |
2015: 21 drugs
| Azilect | 61 | $49,897 | $818 |
| Neupro | 15 | $12,060 | $804 |
| Carbidopa-Levodopa | 269 | $11,575 | $43 |
| Namenda | 24 | $8,680 | $362 |
| Entacapone | 31 | $8,487 | $274 |
| Modafinil | 20 | $5,838 | $292 |
| Pramipexole Er | 13 | $5,794 | $446 |
| Mirapex Er | 12 | $5,485 | $457 |
| Namenda Xr | 13 | $4,658 | $358 |
| Amantadine | 46 | $4,387 | $95 |
| Selegiline | 40 | $4,084 | $102 |
| Carbidopa-Levodopa Er | 50 | $2,992 | $60 |
| Rivastigmine | 15 | $1,803 | $120 |
| Pramipexole Dihydrochloride | 23 | $1,461 | $64 |
| Donepezil | 77 | $624 | $8 |
| Clonazepam | 45 | $543 | $12 |
| Midodrine | 18 | $468 | $26 |
| Fludrocortisone Acetate | 12 | $398 | $33 |
| Gabapentin | 20 | $336 | $17 |
| Ropinirole | 20 | $238 | $12 |
| Lorazepam | 15 | $51 | $3 |
2014: 17 drugs
| Azilect | 39 | $25,031 | $642 |
| Modafinil | 14 | $16,959 | $1,211 |
| Carbidopa-Levodopa | 235 | $13,480 | $57 |
| Entacapone | 28 | $8,854 | $316 |
| Namenda | 30 | $7,386 | $246 |
| Mirapex Er | 17 | $7,056 | $415 |
| Amantadine | 32 | $2,859 | $89 |
| Pramipexole Dihydrochloride | 36 | $2,765 | $77 |
| Rivastigmine | 12 | $2,216 | $185 |
| Selegiline | 25 | $1,911 | $76 |
| Carbidopa-Levodopa Er | 42 | $1,845 | $44 |
| Donepezil | 60 | $1,148 | $19 |
| Topiramate | 12 | $375 | $31 |
| Gabapentin | 19 | $222 | $12 |
| Clonazepam | 31 | $181 | $6 |
| Quetiapine | 11 | $127 | $12 |
| Propranolol | 11 | $41 | $4 |
2013: 13 drugs
| Azilect | 45 | $31,463 | $699 |
| Carbidopa-Levodopa | 215 | $11,686 | $54 |
| Tasmar | 12 | $11,215 | $935 |
| Entacapone | 23 | $10,548 | $459 |
| Mirapex Er | 15 | $6,293 | $420 |
| Amantadine | 32 | $3,231 | $101 |
| Carbidopa-Levodopa Er | 46 | $2,716 | $59 |
| Pramipexole Dihydrochloride | 31 | $1,910 | $62 |
| Selegiline | 16 | $1,416 | $88 |
| Donepezil | 35 | $603 | $17 |
| Gabapentin | 22 | $481 | $22 |
| Clonazepam | 25 | $371 | $15 |
| Quetiapine | 18 | $232 | $13 |
Money from drug and device companies
$17,154 in 2025
| 2025 | 1 | 10 | $15,588 | $17,154 |
| 2023 | 1 | 1 | None | $139 |
| 2022 | 2 | 2 | None | $245 |
| 2020 | 1 | 1 | None | $125 |
| 2019 | 1 | 1 | None | $175 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Eli Lilly and | None | $17,154 | 10 payments
|
See all 10 published payments
| Eli Lilly and | Consulting · 2025-11-19 | None | $9,788 |
| Eli Lilly and | Travel · 2025-11-07 | None | $886 |
| Eli Lilly and | Travel · 2025-11-07 | None | $174 |
| Eli Lilly and | Travel · 2025-11-07 | None | $205 |
| Eli Lilly and | Consulting · 2025-05-12 | None | $5,800 |
| Eli Lilly and | Meals · 2025-05-01 | None | $134 |
| Eli Lilly and | Meals · 2025-05-01 | None | $58 |
| Eli Lilly and | Meals · 2025-05-01 | None | $32 |
| Eli Lilly and | Meals · 2025-05-01 | None | $54 |
| Eli Lilly and | Meals · 2025-05-01 | None | $24 |
See earlier years (2023, 2022, 2020, 2019)
2023: $139
| Medtronic | Percept PC Brainsense | $139 | 1 payment
|
2022: $245
| Insightec | Exablate | $149 | 1 payment
|
| Takeda Pharmaceuticals U.S.A. | Gammagard Liquid | $96 | 1 payment
|
2020: $125
| Medtronic USA | Activa | $125 | 1 payment
|
2019: $175
| Medtronic USA | Activa | $175 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Roche Diagnostics Corporation · Cobas 6000 Core Unit · 2021 | Their institution | $333,398 |
| GENZYME CORPORATION · Multicenter, Randomized, Double-Blind, Placebo Controlled Study To Assess the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Gz/Sar402671 in Patients With Early-Stage Parkinson''S Disease Carrying A Gba Mutation Or Other Pre-Specified Variant · 2020 | Their institution | $40,851 |
| GENZYME CORPORATION · Multicenter, Randomized, Double-Blind, Placebo Controlled Study To Assess the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Gz/Sar402671 in Patients With Early-Stage Parkinson'S Disease · 2019 | Their institution | $25,220 |
| Roche Diagnostics Corporation · Elecsys Troponin T Gen 5 Stat · 2021 | Their institution | $24,000 |
| Roche Diagnostics Corporation · Cd Cobas Reagents · 2020 | Their institution | $13,715 |
| GENZYME CORPORATION · Multicenter, Randomized, Double-Blind, Placebo Controlled Study To Assess the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Gz/Sar402671 in Patients With Early-Stage Parkinson'S Disease Carrying A Gba Mutation Or Other Pre-Specified Variant. · 2020 | Their institution | $2,490 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1114053808
- Licence
- CA A86599California A86599: Current · expires 2027-08-31
- Trained
- Vanderbilt University School of Medicine, 2002
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 2084N0600X (2084N0600X); Neurology (2084N0400X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2007-02-26
- NPI last updated
- 2023-11-13
- NPI record certified
- 2023-11-13
This is when the NPI record was last certified, not a medical board exam.